Frazier Sees Opportunity For New $987m Fund Despite Financial Market Turmoil

Some things have changed since January 2020, when Frazier Life Sciences closed its 10th venture capital fund, totaling $617m, but much remains the same now that the firm has raised its 11th fund, totaling $987m. Despite the macroeconomic and global political issues causing havoc in the public financing market, scientific innovations continue to generate ideas for new start-ups that many investors are eager to finance in anticipation that big pharma companies eventually will buy them.

Also, the COVID-19 pandemic that started in 2020 – which drew investors into the biopharmaceutical industry that were not heavily invested in health care before – does not appear to be near its end. Because of these factors, the robust pace of investment at the private company level has not really slowed down, despite a sharp decline in initial public offerings in 2022 after a second consecutive record-breaking year for IPOs in the US in 2021